An official website of the United States government
Home
Name
Bromocriptine mesylate
Alternate Names
Bromocriptine
Bromocriptine mesilate
Bromocriptine methanesulphonate
Parlodel
Abbreviations
None
Category
Hormones and hormonal mechanisms
Subcategory
Dopamine agonist
NSC Number
None
Primary Site
pituitary gland
Histology
None
Remarks
FDA indications for use of Bromocriptine include Parkinson disease, hyperprolactinemia-associated disfunctions, including prolactin- secreting pituitary adenomas and acromegaly.
In addition to decreasing the prolactin levels in prolactinomas, Bromocriptine can reduce the tumor size. The effect on tumor size in other types of secreting or non-secreting pituitary tumors is controversial. In acromegaly, it can decrease the growth hormone by 50% in half of the cases but generally, not the tumor size.
Code Bromocriptine as Hormonal therapy in prolactinomas. For other pituitary tumors, code if a medical provider stated it is given to decrease or control the tumor size.
In addition to decreasing the prolactin levels in prolactinomas, Bromocriptine can reduce the tumor size. The effect on tumor size in other types of secreting or non-secreting pituitary tumors is controversial. In acromegaly, it can decrease the growth hormone by 50% in half of the cases but generally, not the tumor size.
Code Bromocriptine as Hormonal therapy in prolactinomas. For other pituitary tumors, code if a medical provider stated it is given to decrease or control the tumor size.
Coding
Please see remarks for additional information
